SCHEMBL4287426

SCHEMBL4287426

O=C(O)c1cc2cc[nH]c(=O)c2c2cc3c(cc12)OCO3.O=C(O)c1cc2cc[nH]c(=O)c2c2cc3ccccc3cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.45
CYP1A2 P05177 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 1/20 0.45
DHODH Q02127 1/20 0.44
CHEK1 O14757 8/20 0.41
KEAP1 Q14145 1/20 0.39
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
MC4R P32245 1/20 0.37
PPARG P37231 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
PARP1 P09874 2/20 0.36
NAPRT Q6XQN6 1/20 0.35
TNKS O95271 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287142 0.94 CHEK1 (0.44) TP53CYP1A2SMN1; SMN2HIF1ADHODH
SCHEMBL4287238 0.89 CHEK1 (0.48) TP53CYP1A2HIF1ACHEK1KEAP1
SCHEMBL5025815 0.78 KDM4E (0.51) SMN1; SMN2CHEK1KEAP1KMT2AKDM4E
SCHEMBL4295221 0.76 CHEK1 (0.46) CHEK1KDM4E
SCHEMBL4288965 0.74 CHEK1 (0.50) DHODHCHEK1KDM4E
SCHEMBL4296227 0.73 CHEK1 (0.54) CHEK1KDM4EPOLBGAANAPRT
SCHEMBL4302533 0.71 CHEK1 (0.73) DHODHCHEK1KMT2AMEN1RXFP1
SCHEMBL4296686 0.71 CHEK1 (0.73) TP53CYP1A2HIF1ACHEK1KDM4E
SCHEMBL4292052 0.71 CHEK1 (0.65) TP53CYP1A2SMN1; SMN2HIF1ACHEK1
SCHEMBL4294445 0.71 CHEK1 (0.58) SMN1; SMN2CHEK1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258852-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258852-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, CDKN1A TP53 71/4885CYP1A2 4176/4885SMN1; SMN2 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.